Head-To-Head Survey: Compass Therapeutics (NASDAQ:CMPX) versus Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) and Compass Therapeutics (NASDAQ:CMPX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares Vericel and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Compass Therapeutics	N/A	-38.71%	-34.72%

Valuation & Earnings

This table compares Vericel and Compass Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26 million	7.45	$16.52 million	$0.47	85.55
Compass Therapeutics	$850,000.00	387.72	-$66.49 million	($0.40)	-4.58

Vericel has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vericel has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Vericel and Compass Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	2	4	0	2.67
Compass Therapeutics	1	1	13	1	2.88

Vericel presently has a consensus target price of $58.40, indicating a potential upside of 45.24%. Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 543.13%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Vericel.

Institutional & Insider Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vericel beats Compass Therapeutics on 8 of the 15 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.